Skip to Content
 

News: October, 2017

My Cancer Genome launches new search tool for clinical trials

Friday, October 27th, 2017

My Cancer Genome (MCG), a web-based cancer information tool developed by Vanderbilt-Ingram Cancer Center investigators in 2011 and supported by GenomOncology, has launched a new clinical trial search tool that allows website visitors to search for cancer clinical trials based on disease, biomarker, phase and recruiting status.

New faculty profile: Tuya Pal, M.D.

Friday, October 27th, 2017

Tuya Pal, M.D., associate professor of medicine and Ingram Associate Professor of Cancer Research., specializes in cancer genetics and health disparities among diverse populations.

Study to test combination therapy for breast cancer

Friday, October 27th, 2017

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR T therapy

Wednesday, October 25th, 2017

Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

Symposium honors Moses’ storied cancer research career

Friday, October 20th, 2017

Members of the Vanderbilt University Medical Center (VUMC) community and others whose lives and careers have been influenced by legendary cancer investigator, educator and administrator Harold (Hal) Moses, M.D., have endowed the Linda and Harold L. Moses, M.D., Career Development Fund.

Calcium intake and colorectal cancer

Friday, October 20th, 2017

Calcium plays key roles in cellular signaling, proliferation and death. Previous studies exploring the relationship between dietary calcium intake and colorectal cancer have had contradictory results, perhaps due to no consideration of variation in calcium reabsorption by the kidney.

Researchers find novel mechanism of resistance to anti-cancer drugs

Friday, October 20th, 2017

The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.

Funding Opportunity – American Cancer Society-Institutional Research Grant (IRG)

Tuesday, October 10th, 2017

Description of Program Applications are being solicited for support by the American Cancer Society‐Institutional Research Grant (IRG). These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have external grant support. The ACS defines junior faculty as investigators at the rank of assistant […]

Predators’ fund powers fight against childhood cancer

Friday, October 6th, 2017

Nashville Predators goaltender Pekka Rinne, Predators executive leaders, executives from Tri Star Energy (Twice Daily) and team mascot Gnash recently presented the proceeds of the team’s 365 Pediatric Cancer Fund to Monroe Carell Jr. Children’s Hospital at Vanderbilt.

Boosting sarcoma cell death

Friday, October 6th, 2017

A recent study by Dai Chung, M.D., and colleagues suggests new therapeutic options for Ewing sarcoma, a type of rare, aggressive childhood cancer.

Next Page »